Puma Biotechnology, Inc. (PBYI) — Analyst outlook / Analyst consensus target is. Based on 19 analyst ratings, the consensus is bullish — 8 Buy, 7 Hold, 4 Sell.
Analysts estimate Earnings Per Share (EPS) of $0.30 and revenue of $0.22B for the next fiscal year.
Earnings Per Share (EPS) track record: 2024: actual $0.62 vs est $0.30 (beat +106.7%). 2025: actual $0.62 vs est $0.55 (beat +12.7%). Analyst accuracy: 69%.
PBYI Analyst Ratings
Buy
Based on 19 analysts giving stock ratings to Puma Biotechnology, Inc. in the past 3 months
EPS Estimates — PBYI
69%
Analyst Accuracy
Fair
2 years compared
Actual vs Estimate
2024
Actual $0.62
vs Est $0.30
▲ 51.6% off
2025
Actual $0.62
vs Est $0.55
▲ 11.3% off
Profitability Outlook
Company is profitable but with thin earnings per share.
Revenue Estimates — PBYI
97%
Analyst Accuracy
Accurate
2 years compared
Actual vs Estimate
2024
Actual $0.230B
vs Est $0.224B
▲ 2.9% off
2025
Actual $0.228B
vs Est $0.222B
▲ 3.0% off
Revenue Trend
Revenue has been relatively flat. Analysts expect stable revenue going forward.
